Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge

被引:23
|
作者
Veltri, RW
Miller, MC
Mangold, LA
O'Dowd, GJ
Epstein, JI
Partin, AW
机构
[1] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21205 USA
[2] Immunicon Corp, Huntingdon, PA USA
[3] UroCor Inc, Oklahoma City, OK USA
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 01期
关键词
prostate; prostatic neoplasms; prostate-specific antigen; tumor markers; biological; neoplasm staging;
D O I
10.1016/S0022-5347(05)64839-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We developed an algorithm for predicting the likelihood of organ confined disease in patients with clinical stage T1c prostate cancer using biopsy pathology, computer assisted image analysis and serum prostate specific antigen (PSA). Materials and Methods: Of the 557 consecutive men enrolled in this study between October 1998 and January 2000 scheduled for radical prostatectomy at a single institution 386 (69%) presented with clinical stage T1c disease. Study exclusion criteria included neoadjuvant hormonal treatment with luteinizing hormone-releasing hormone, antiandrogen or 5alpha-reductase inhibitors. Preoperative serum, biopsy histology slides, clinical demographic information, prostatectomy pathology and prostate weight data were obtained. Biomarkers assessed included total PSA, complexed PSA, free PSA, the free-to-total PSA ratio, quantitative nuclear grade determined by image analysis, complexed PSA density, and biopsy Gleason grade and score. To determine patient specific quantitative nuclear grade values, images from approximately 125 cancer nuclei were captured per patient from the area of the biopsy section with the highest Gleason score. The variance in 60 nuclear size, shape and chromatin texture descriptors was calculated for each gallery of nuclei. Logistic regression was done to determine the most accurate combination of variables for predicting organ confined prostate cancer. Results: Complete results and data were available on 255 of the 386 men (66%) with an average age plus or minus standard deviation of 58.8 +/- 6 years who had stage T1c disease, including 49 (19%) with pathologically nonorgan confined disease. Logistic regression analysis revealed that quantitative nuclear grade, biopsy Gleason score, total PSA, the calculated free-to-total PSA ratio, complexed PSA and complexed PSA density were univariately significant for predicting organ confined disease (p < 0.05). On backward stepwise logistic regression only quantitative nuclear grade, complexed PSA density and Gleason score remained in a model yielding an area under the receiver operating characteristics curve of 82.4%. Conclusions: The quantitative nuclear grade biomarker was the strongest independent predictor of pathological stage in men with clinical stage T1c prostate cancer when combined with biopsy Gleason score and complexed PSA density data.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 50 条
  • [31] Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer
    Charles R. Pound
    Patrick C. Walsh
    Jonathan I. Epstein
    Daniel W. Chan
    Alan W. Partin
    World Journal of Urology, 1997, 15 : 373 - 377
  • [32] Clinicopathologic trends of patients with clinical stage T1c submitted to radical prostatectomy in Brazil
    Billis, A.
    Bronner, M. N.
    Galvao, M. F.
    Schultz, L.
    Magna, L. A.
    Ferreira, U.
    MODERN PATHOLOGY, 2007, 20 : 138A - 138A
  • [33] Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy
    Ozawa, Yu
    Nohara, Sunao
    Nakamura, Ken
    Hattori, Seiya
    Yagi, Yasuto
    Nishiyama, Toru
    Yorozu, Atsunori
    Monma, Tetsuo
    Saito, Shiro
    PROSTATE, 2024, 84 (05): : 502 - 510
  • [34] Clinical and pathologic significance of T1c adenocarcinoma of the prostate cancer
    BH Bochner
    DG Skinner
    G Lieskovsky
    Prostate Cancer and Prostatic Diseases, 1999, 2 : S7 - S7
  • [35] Clinical and pathologic significance of T1c adenocarcinoma of the prostate cancer
    Bochner, BH
    Skinner, DG
    Lieskovsky, G
    PROSTATE CANCER AND PROSTATIC DISEASES, 1999, 2 (Suppl 3) : S7 - S7
  • [36] Pathological parameters of radical prostatectomy for at clinical stages T1c versus T2 prostate adenocarcinoma: Decreased pathological stage and increased detection of transition zone tumors
    Jack, GS
    Cookson, MS
    Coffey, CS
    Vader, V
    Roberts, RL
    Chang, SS
    Smith, JA
    Shappell, SB
    JOURNAL OF UROLOGY, 2002, 168 (02): : 519 - 524
  • [37] Change in prostate cancer grade over time in men followed expectantly for stage T1c disease
    Sheridan, T. B.
    Epstein, J. I.
    MODERN PATHOLOGY, 2007, 20 : 175A - 176A
  • [38] Change in prostate cancer grade over time in men followed expectantly for stage T1c disease
    Sheridan, T. B.
    Epstein, J. I.
    LABORATORY INVESTIGATION, 2007, 87 : 175A - 176A
  • [39] Change in prostate cancer grade over time in men followed expectantly for stage T1c disease
    Sheridan, Todd B.
    Carter, H. Ballentine
    Wang, Wenle
    Landis, Patricia B.
    Epstein, Jonathan I.
    JOURNAL OF UROLOGY, 2008, 179 (03): : 901 - 904
  • [40] Prediction by quantitative histology of pathological stage in prostate cancer
    Pepe, P
    Galia, A
    Fraggetta, F
    Grasso, G
    Allegro, R
    Aragona, F
    EJSO, 2005, 31 (03): : 309 - 313